DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 450 participants.

Also called NCT05764057

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 450 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05764057
  • EudraCT 2022-001901-28
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05764057. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-12 (actual); primary completion 2026-10-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Acronym
DAPAPROTECTOR
Condition
AMI
Condition
STEMI
Condition
NSTEMI
Condition
Left Ventricular Dysfunction
Intervention (Drug)
Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)
Intervention (Drug)
Placebo comparator
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct05764057
Content hash
a0e18264eaa6c92877ae9c8c5ea55ad74f197dd294a9a7f8414890f19b6e0e65